As a novel identified adipocytokine recently, asprosin has been considered to be a potential biomarker for abnormal glucolipid metabolic disorders such as obesity and type 2 diabetes. The gene discussed is FBN1; the disease is obesity due to melanocortin 4 receptor deficiency.